Natural history of pertussis antibody in the infant and effect on vaccine response
- PMID: 2313127
- DOI: 10.1093/infdis/161.3.487
Natural history of pertussis antibody in the infant and effect on vaccine response
Abstract
To better characterize the transplacental transfer and persistence of pertussis antibodies and their role in the immune response to vaccine, concentrations of pertussis agglutinins and antibodies to lymphocytosis promoting factor (LPF) and filamentous hemagglutinin (FHA) were measured in three distinct groups of serum. Transplacental pertussis IgG antibody concentrations in newborns were found to be comparable to corresponding maternal concentrations and to decline with a half-life of approximately 6 weeks. By the age of 4 months, most infants had no detectable antibodies to LPF or FHA. Higher concentrations of maternally derived antibody to LPF were associated with a significantly weaker antibody response to conventional vaccine. In contrast, acellular vaccine stimulated superior antibody production, regardless of antecedent concentrations of antibody to LPF. The data support continuation of the current schedule of pertussis immunization and further efforts to develop an acellular vaccine for use in young infants.
Comment in
-
Pertussis and its prevention: a family affair.J Infect Dis. 1990 Mar;161(3):473-9. doi: 10.1093/infdis/161.3.473. J Infect Dis. 1990. PMID: 2179422 Review. No abstract available.
Similar articles
-
Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.Dev Biol Stand. 1985;61:353-65. Dev Biol Stand. 1985. PMID: 2872124
-
Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum.J Infect Dis. 2004 Jul 15;190(2):335-40. doi: 10.1086/421033. Epub 2004 Jun 14. J Infect Dis. 2004. PMID: 15216470
-
Immunogenicity of a three-component acellular pertussis vaccine administered at birth.Pediatrics. 2003 May;111(5 Pt 1):1042-5. doi: 10.1542/peds.111.5.1042. Pediatrics. 2003. PMID: 12728086 Clinical Trial.
-
Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.Dev Biol Stand. 1985;61:469-75. Dev Biol Stand. 1985. PMID: 2872128
-
Pertussis: an important target for maternal immunization.Vaccine. 2003 Jul 28;21(24):3483-6. doi: 10.1016/s0264-410x(03)00356-6. Vaccine. 2003. PMID: 12850365 Review.
Cited by
-
Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.Infect Immun. 2001 Aug;69(8):5010-5. doi: 10.1128/IAI.69.8.5010-5015.2001. Infect Immun. 2001. PMID: 11447180 Free PMC article.
-
Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec -routine care evidence.Gene Ther. 2023 Feb;30(1-2):101-106. doi: 10.1038/s41434-022-00339-0. Epub 2022 Apr 27. Gene Ther. 2023. PMID: 35474244
-
Specific antibodies against vaccine-preventable infections: a mother-infant cohort study.BMJ Open. 2013 Apr 11;3(4):e002473. doi: 10.1136/bmjopen-2012-002473. Print 2013. BMJ Open. 2013. PMID: 23585389 Free PMC article.
-
Human teratogens update 2011: can we ensure safety during pregnancy?Birth Defects Res A Clin Mol Teratol. 2012 Mar;94(3):123-8. doi: 10.1002/bdra.22887. Epub 2012 Feb 13. Birth Defects Res A Clin Mol Teratol. 2012. PMID: 22328359 Free PMC article. Review.
-
Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and 3 its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 study.EClinicalMedicine. 2024 Mar 28;71:102556. doi: 10.1016/j.eclinm.2024.102556. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38586589 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
